Log in

Cytosorbents Stock Price, Forecast & Analysis (NASDAQ:CTSO)

$4.25
-0.20 (-4.49 %)
(As of 11/15/2019 01:04 AM ET)
Today's Range
$4.23
Now: $4.25
$4.57
50-Day Range
$4.27
MA: $4.78
$5.32
52-Week Range
$3.68
Now: $4.25
$11.20
Volume133,000 shs
Average Volume148,340 shs
Market Capitalization$137.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$0.21 per share

Profitability

Net Income$-17,210,000.00

Miscellaneous

Employees125
Market Cap$137.80 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.


Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) released its quarterly earnings data on Tuesday, November, 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.08. The medical research company earned $6.10 million during the quarter, compared to analysts' expectations of $6.49 million. Cytosorbents had a negative return on equity of 165.00% and a negative net margin of 87.79%. View Cytosorbents' Earnings History.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cytosorbents.

What price target have analysts set for CTSO?

3 Wall Street analysts have issued twelve-month price targets for Cytosorbents' shares. Their forecasts range from $10.00 to $15.00. On average, they anticipate Cytosorbents' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 205.9% from the stock's current price. View Analyst Price Targets for Cytosorbents.

What is the consensus analysts' recommendation for Cytosorbents?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.

What are Wall Street analysts saying about Cytosorbents stock?

Here are some recent quotes from research analysts about Cytosorbents stock:
  • 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019)

Has Cytosorbents been receiving favorable news coverage?

News stories about CTSO stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytosorbents earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cytosorbents.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:
  • Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
  • Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
  • Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
  • Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Skylands Capital LLC (2.40%), Sargent Investment Group LLC (0.92%), Bradley Foster & Sargent Inc. CT (0.14%), Crow Point Partners LLC (0.13%) and Cadence Capital Management LLC (0.04%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

Which institutional investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Bradley Foster & Sargent Inc. CT, Sargent Investment Group LLC and Crow Point Partners LLC. View Insider Buying and Selling for Cytosorbents.

Which institutional investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC and Cadence Capital Management LLC. View Insider Buying and Selling for Cytosorbents.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $4.25.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $137.80 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents.

What is Cytosorbents' official website?

The official website for Cytosorbents is http://www.cytosorbents.com/.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel